Case number 1:25-cv-00349
Bayer Pharma AG et al v. Lupin Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 16, 2025 | N/A | CORRECTING ENTRY: The disclosure statement filed on 5/15/2025, at D.I. 8 has been removed from the docket. Upon review it was determined other affiliates were not added for Defendant Lupin Pharmaceuticals, Inc.. Lupin, Inc. and Nanomi B.V. should have been inputted. Counsel is to refile the disclosure accordingly. (nms) (Entered: 05/16/2025) (0) |
| May 16, 2025 | 10 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Limited and Other Affiliates Nanomi B.V. and Lupin, Inc. for Lupin Pharmaceuticals, Inc., filed by Lupin Limited, Lupin Pharmaceuticals, Inc.. (Haney, Megan) Modified on 5/19/2025 (nms). (Entered: 05/16/2025) (2) |
| May 15, 2025 | 9 | STIPULATION to Extend the Time to Answer, Move or Otherwise Respond to Complaint - filed by Lupin Limited, Lupin Pharmaceuticals, Inc.. (Phillips, John) Modified on 5/15/2025 (nms). (Entered: 05/15/2025) (2) |
| May 15, 2025 | N/A | SO ORDERED, re 9 STIPULATION to Extend the Time to Answer, Move or Otherwise Respond to Complaint (*Reset Answer Deadlines: Lupin Limited answer due 7/21/2025; Lupin Pharmaceuticals, Inc. answer due 7/21/2025). Signed by Judge Richard G. Andrews on 5/15/2025. (nms) (Entered: 05/15/2025) (0) |
| Mar 26, 2025 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) (Entered: 03/26/2025) (0) |
| Mar 21, 2025 | N/A | Remark: The MDL Panel has been notified. (cdd) (Entered: 03/21/2025) (0) |
| Mar 20, 2025 | 1 | COMPLAINT with Jury Demand against Lupin Limited, Lupin Pharmaceuticals, Inc. (Filing fee $ 405, receipt number ADEDC-4641999) - filed by Bayer Pharma AG, Bayer AG, Janssen Pharmaceuticals, Inc. (Attachments: # 1 Exhibits A-E, # 2 Civil Cover Sheet)(cdd) (Entered: 03/20/2025) (0) |
| Mar 20, 2025 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (cdd) (Entered: 03/20/2025) (3) |
| Mar 20, 2025 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/22/2023. Date of Expiration of Patent: (See Form). (cdd) (Entered: 03/20/2025) (1) |
| Mar 20, 2025 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,828,310 B2. (cdd) (Entered: 03/20/2025) (1) |
| Mar 20, 2025 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceuticals, Inc. filed by Janssen Pharmaceuticals, Inc. (cdd) (Entered: 03/20/2025) (1) |
| Mar 20, 2025 | 6 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bayer AG for Bayer Pharma AG filed by Bayer AG, Bayer Pharma AG. (cdd) (Entered: 03/20/2025) (1) |
| Mar 20, 2025 | 7 | Summons Issued as to Lupin Limited on 3/20/2025; Lupin Pharmaceuticals, Inc. on 3/20/2025. (Attachments: # 1 Summons Issued)(cdd) (Entered: 03/20/2025) (0) |
